↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Seaport Therapeutics$SPTX · filed: 🫧 Edgar looked up Seaport TherapeuticsCheck ▾Close ▴
What Seaport Therapeutics filed
🫧 Edgar looked up Seaport Therapeutics, Inc. ($SPTX). Last filing: 10-Q, 2026-11-02. 4 event filings (8-K) in the past twelve months. Every figure links to the filing it came from on Seaport Therapeutics’s card.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Seaport's **$201M** IPO tests whether institutions will fund mid-stage neuropsych plays in a compressed biotech window.
$201 million
IPO this week
11.8 million
shares at a midpoint of
$17
placing its post-money valuation near
$850 million
Seaport's lead asset
Seaport Therapeutics filed terms for a $201 million IPO this week, pricing expected within 72 hours. The Boston-based neuropsychiatric therapeutics company joins a sparse biotech IPO calendar that has seen only four life sciences pricings in the trailing 90 days.
The company is offering 11.8 million shares at a midpoint of $17, placing its post-money valuation near $850 million. Seaport's lead asset, SPN-830, targets major depressive disorder with a rapid-onset oral formulation designed to compete against esketamine nasal spray and legacy SSRIs. Phase 2 data published in October showed statistically significant reduction in MADRS scores at 48 hours, a timeline that matters in acute care settings. The company also holds rights to SPN-812, a non-stimulant ADHD candidate licensed from Supernus Pharmaceuticals under a milestone-based deal that includes $45 million in near-term payments.
The pricing comes as biotech IPO windows compress. Year-to-date life sciences issuance stands at $2.1 billion across 14 deals, down 38% from the same period in 2023. Institutional appetite has narrowed to late-stage assets with visible commercial pathways or platform economics that scale across indications. Seaport sits in the middle: a clinical-stage play with one lead program in Phase 2 and a second asset still under regulatory review for pediatric ADHD. The company burned $62 million in the trailing twelve months and holds $89 million in cash pre-IPO, giving it roughly 18 months of runway at current spend.
What allocators are watching is whether Seaport can attract crossover funds that have largely stayed on the sidelines since the biotech correction of 2022. The IPO syndicate includes Goldman Sachs, Jefferies, and Leerink Partners, all of which have placed similar-sized neuropsychiatry deals in the past 24 months. Pricing discipline will matter. If Seaport prices at or above midpoint, it signals that institutional buyers see differentiation in the rapid-onset depression mechanism. If it prices below $16, the market is treating this as a binary Phase 3 bet with limited visibility.
The broader context is that psychiatric therapeutics are seeing renewed capital interest after years of clinical failures. Johnson & Johnson's Spravato generated $1.05 billion in 2023 sales, proving commercial viability for faster-acting depression treatments. Axsome Therapeutics trades at $79, up 110% from its 2023 lows, after back-to-back approvals in depression and migraine. Seaport is positioning itself as the next wave, but it enters a market where differentiation is hard and reimbursement fights are long.
Operators should track three things: whether Seaport prices in the top half of its range by end of week, whether the stock holds its debut price through the first 10 trading days, and whether the company announces a Phase 3 trial start for SPN-830 within six months. That last point is the real signal. No Phase 3, no institutional follow-on. Biotech windows close faster than they open, and Seaport has roughly $200 million in new cash to prove it can reach a pivotal dataset before the next fundraise.
Branded by POPS4 · proof in 60 seconds
For the principal
Track pricing and day-10 hold; neuropsych differentiation is hard and this round buys 18 months, not commercialization.
For the operator
If it prices above $17, crossover funds are back; below $16 means binary Phase 3 bet with limited institutional support.
For the house
Watch for Phase 3 announcement within six months; no pivotal trial means no follow-on positioning for named accounts.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.